LEAMINGTON, Ontario and CANTANHEDE, Portugal, Oct. 5, 2022 -PRESS RELEASE - Tilray Brands, Inc., a global cannabis company inspiring and empowering the worldwide community to live their very best life, announced that it has successfully relaunched its EU GMP-produced medical cannabis oral solution in Ireland under the country’s Medical Cannabis Access Program (MCAP). Tilray’s approved product has also recently received reimbursement approval, which gives patients cost reimbursement and ensures more eligible patients can access quality medical cannabis under Ireland’s MCAP.
Denise Faltischek, Tilray Brands’ chief strategy officer and head of international business, said, “We are extremely proud to relaunch in Ireland with an expanded footprint. The MCAP reimbursement approval is a tremendous step in providing patients with greater access to Tilray’s high-quality medical cannabis products that address their needs. We remain dedicated to do our part to increase access for patients in need around the world.”
Patients in Ireland may now access Tilray’s full-spectrum medical cannabis oil solution through the MCAP. Tilray intends to supply Irish patients with its full suite of medical cannabis products when local regulations allow.
Tilray Medical provides EU-GMP-certified medical cannabis products in 22 countries with a comprehensive portfolio of THC and CBD products. Each medical cannabis product that Tilray offers has been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to the supply of their medicinal cannabis products.
